mercredi 11 mars 2020

Onco Actu du 11 mars 2020


2. ETIOLOGIE



Higher Concentrations Of IGF-1 Are A Probable Cause of Breast Cancer [Annals of Oncology Press Release]











3.1.1 PRÉVENTION - TABAC - E-CIGS



FDA Warns Retailers, Manufacturers to Remove Unauthorized E-Cigarette Products from Market [FDA]











4.1 DÉP., DIAG. & PRONO. - PROSTATE



Prostate Cancer: Combined Biopsy Strategy Makes for More Accurate Diagnosis [NIH Director's Blog]










4.16 DÉP., DIAG. & PRONO. - PANCRÉAS



New Study Identifies Valuable Tool for Treating Pancreatic Cancer Patients [University of Colorado]











4.2 DÉP., DIAG. & PRONO. - GÉNOME



Older women with breast cancer may benefit from genetic testing [Stanford Medicine]










Inherited Mutations in Postmenopausal Breast Cancer Patients Suggest Genetic Testing Is Warranted [Genome Web]











Genetic test could pick out 'ultra high risk' bone marrow cancer patients [Institute of Cancer Research]











4.7 DÉP., DIAG. & PRONO. - COL DE L'UTÉRUS



Roche receives FDA approval for CINtec PLUS Cytology test to aid clinicians in improving cervical cancer prevention [Roche]











4.9 DÉP., DIAG. & PRONO. - SEIN



Tomosynthesis Outperforms Digital Mammography in Five-Year Study [RSNA]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



Possible breast cancer treatment could go to clinical trial immediately as scientists spot target in 'normal' cells [University of Sussex]











5.10 TRAITEMENTS - ESSAIS



FDA’s Draft Guidance Will Improve Evidence Base for Older Adults with Cancer [ASCO]











5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



US Patent Covering CRISPR-Edited Allogeneic CAR T-Cells Granted to Cellectis [Cellectis]











J&J's favorite CAR-T developer, currently owned by a Chinese CRO, is laying the groundwork for US IPO [EndPoints]











5.2 PHARMA



Takeda's Ninlaro swings and misses in newly diagnosed myeloma [Fierce Pharma]











2 newer multiple myeloma drugs fall short in bid for wider market [Biopharma Dive]










Takeda Provides Update on TOURMALINE-MM2 Phase 3 Trial [Takeda]











5.2.6 PHARMA - BIOTECH



Karyopharm's controversial Xpovio could see wider myeloma market after latest trial win [Fierce Pharma]











6. LUTTE CONTRE LES CANCERS



National Comprehensive Cancer Network Releases Recommendations for Standardizing Quality Measurements in Oncology [NCCN]











6.1 OBSERVATION



Dramatic increase in bowel cancer in young adults in England [University of Bristol]











Disparities in childhood cancer survival biggest for most-treatable tumors [Reuters]











6.9 CONTROVERSES



Want to do better science? Admit you’re not objective [Nature]